Over the last several years there have been a number of exciting breakthroughs and advancements in the diagnosis, treatment and care of oncology patients. Depending on which information you read there are about 1800 “oncology” compounds in various places with the drug development pipeline. It is expected that there will be a relatively large explosion of molecules coming to market over the next decade. When combined with the expected dynamic where Primary Care Physicians will be more involved with the management of Oncology patients, the industry will be requiring the redeployment of representatives into the oncology milieu.

This program and McGill University Oncology I are required to receive Oncology certification from CCPE. Please click here to go to the Oncology I page. You can choose to register for both McGill University Oncology I & II at the same time, however McGill University Oncology I is a prerequisite to II.

This program represents a departure from the standard CCPE paper based courses in a number of ways including:
  • The program is administered entirely on-line. Program content and exams are all delivered by the CCPE Learning Management System. (Previous CCPE students will recognize use of the LMS from taking their online exams.)
  • There is an exam for each module. That way you can learn the relevant material, take the exam and move onto the next module: reducing the amount of material required to study and less pressure than having one “Big Exam” at the end of the course.
  • Completing the program requires students to complete all module exams on-line where results from each module exam will contribute to the overall course grade.
  • Students will need to successfully complete both Oncology I and Oncology II (this course) to be certified in Oncology. (the completion of both programs is required for CCPE awards and medals)
  • Physicians, allied healthcare workers and McGill University Medical Students, interns and residents are taking this course. You will learn what they are learning!
Product Details

Course Name
McGill University Oncology II

8 modules E-Learning on MyCCPE portal
Suggested number of hours of study: 30
Timeline: 6 months to complete the entire course

NOTE: Click on the headers below to expand

Module 10: Prostate Cancer

Prostate cancer is the most frequently diagnosed non-cutaneous adult male malignancy. This module will discuss the symptoms and risks factors associated with the disease, the pros and cons of screening, the patients' stratification process, and the prognosis and treatment of prostate cancer.
After reading this module, you should be able to:
  1. Identify the risk factors for the development of prostate cancer.
  2. Stratify patients based on risk for prostate cancer.
  3. Describe the pros and cons of screening for prostate cancer.
  4. Describe the signs and symptoms of prostate cancer.
  5. Describe the prognosis and treatment of prostate cancer.

Module 11: Bladder & Kidney Cancers

In Canada, bladder and kidney cancers are the sixth and ninth most common cancers respectively. This module discusses the etiology and risk factors associated with the diseases, as well as advances in the diagnosis and treatment of bladder and kidney cancers. After reading this module, you should be able to:
  1. Identify the major risk factors for the development of bladder and kidney cancers.
  2. Identify the different types of bladder and kidney cancers.
  3. Identify important diagnostic tests and referral criteria.
  4. Identify treatment strategies.

Module 12: Skin Cancer & Sarcoma

The skin can be considered to be the largest organ in the body. During a person’s lifetime, the risk of developing cancer of the skin approaches 20%. Approximately 97% of skin cancers are non-melanoma skin cancers. Melanoma represents approximately 4% of skin cancers and sarcomas about 1% of all cancers. After reading this module you should be able to:
  1. Explain why skin cancer has the highest incidence of all cancer types.
  2. Describe the two main sub-types of non-melanoma skin cancer.
  3. Explain the importance of early diagnosis of malignant melanoma.
  4. Understand the difference between soft tissue sarcoma and bone sarcoma.
  5. Appreciate the importance of early and complete surgical resection of malignant melanoma.
  6. Explain the importance of combination therapy for different types of sarcomas.

Module 13: Gynecological Cancers

In developing countries where human papillomavirus (HPV) screening is not available, cervical cancer is the most common cancer of the female genital tract and the second most common cancer among women in general. In Canada, the most common malignancy of the female genital tract, accounting for 6% of all cancers in women, is endometrial cancer. The leading cause of death due to gynecological cancers among women in developed countries is ovarian cancer, due to the fact that 75% of ovarian cancers are diagnosed at advanced stages. After reading this module, you should be able to:
  1. Describe the etiology and risk factors for the development of endometrial and cervical cancer.
  2. Describe the challenges and methods in the diagnosis and screening of cervical, endometrial and ovarian cancers.
  3. Identify the signs and symptoms of cervical, endometrial and ovarian cancers.
  4. Describe the staging of the cancers.
  5. Describe the prognosis, treatment and follow up procedures for cervical, endometrial and ovarian cancers.

Module 14: Pancreas and Livers Cancers

The liver and pancreas are two large exocrine and endocrine organs of the body. They are located in close proximity to each other. Cancers of these organs are highly malignant and affect functioning of the whole organism early on. The liver is also one of the most common organs for metastatic disease from primary cancers of other tissues and organs. After reading this module, you should be able to:
  1. Differentiate the types of pancreatic cancer and distinguish the major types of hepatobiliary cancers.
  2. Describe the etiology, risk factors, and recommended screening guidelines for pancreatic and liver cancers.
  3. Identify the primary tumors that commonly metastasize to the liver.
  4. Discuss patient presentation and diagnostic tests for pancreatic and liver cancers.
  5. Explain the histopathology and staging of pancreatic and liver cancers.
  6. Describe treatment strategies for pancreatic cancer and liver cancers.

Module 15: Neoplasms of the Central Nervous System

Tumors of the central nervous system (CNS) may be either primary or secondary.
Primary CNS tumors originate from different tissues of the brain or spinal cord. Together they account for fewer than 2% of all tumors and 2.3% of cancer-related deaths. Secondary brain tumors are metastases from tumors of other organs and tissues. Brain tumors remain very difficult to treat in spite of advances in chemotherapy, surgical treatments, radio-oncological treatments, and increased understanding of pathophysiology. A multidisciplinary management approach is required. After reading this module, you should be able to:
  1. Describe the difference between primary and secondary tumors of the central nervous system.
  2. Identify the principal primary brain cancer groups.
  3. Discuss the diagnosis of primary and secondary tumors of the brain.
  4. Describe the signs and symptoms of primary and secondary tumors of the brain.
  5. Explain the treatment of primary and secondary tumors of the brain.

Module 16: Esophageal & Gastric Cancers

The stomach and esophagus are organs of the upper gastrointestinal (GI) tract. The tissues of these organs are exposed to elements in the external environment, namely food, toxins and bacteria. This exposure may facilitate inflammatory processes and the formation of premalignant conditions, which may subsequently lead to the development of cancer. After reading this module, you should be able to:
  1. List the risk factors for developing gastric cancer.
  2. Describe the risk factors associated with squamous cell carcinoma and adenocarcinoma of the esophagus.
  3. Identify the screening tests for gastric cancer.
  4. Describe the staging and prognosis for gastric cancer.
  5. Explain the treatment for gastric cancer.
  6. Discuss diagnostic testing for esophageal cancer.
  7. Identify the signs and symptoms of esophageal cancer.
  8. Explain the management of localized and metastatic esophageal cancer.

Module 17: Myelodysplastic Syndromes/Myeloproliferative Neoplasms (MDS/MPN)

Chronic myeloproliferative neoplasms (MPN) and myelodysplastic syndromes (MDS) have only recently been recognized as cancers. Both MPN and MDS are clonal disorders arising from a single pluripotent stem cell within the hematopoietic system. These conditions have variable phenotypic expression and variable clinical severity, ranging from mild conditions to rapidly progressing malignant disorders. MPN and MDS are considered two separate groups of diseases, however, there is some overlap between them. After reading this module, you should be able to:
  1. Explain the etiology and pathogenesis of the common forms of myeloproliferative neoplasms (MPNs).
  2. Describe the epidemiology and risk factors of myelodysplastic syndromes (MDS).
  3. Identify the signs and symptoms of MPN and MDS.
  4. Discuss and list the investigative tests essential for diagnosis of MPN disorders and MDS.
  5. Explain the differential diagnosis for MPNs.
  6. Identify the main categories and risk groups of MDS.
  7. Distinguish the treatment of lower risk and higher risk MDS.
  8. Distinguish the course and prognosis of different MPN disorders.
  9. Explain supportive care available for all MDS patients.
  10. Describe the treatment approaches appropriate for MPN disease stage.

C.E. Units
3 credits (What is this?)

Key Objectives
After completing the course, students will be able to:

  • Discuss the epidemiology, detection, diagnosis, and treatment of carious types of cancer

Register for this course using our secured online registration form

Corporate Members: $452.00
Corporate Non-Members: $2,260.00

For credit card payment process, shipping costs and return policy click here

Exam Details

Type of Exam
Multiple Choice

Number of questions
8 individual module exams (totaling 76 multiple-choice questions)

Time Limit
Based on individual modules (10 minutes to 30 minutes per module)
6 months to complete the entire course

Passing Grade


helpWant to know more?
Contact us